Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori

February 9, 2024 updated by: Mohamed Alaa, Ain Shams University

The aim of this study is to:

• Evaluation of efficacy and safety of adding black seed oil with vonoprazan triple therapy ( vonoprazan ,clarithromycin and amoxicillin ) in eradication of Helicobacter pylori infection and this will be done through evaluation of:

A. Efficacy by:

  1. determination of successful eradication,which will be considered to be achieved on the basis of a negative stool antigen test four weeks after the end of treatment using Stool Ag test
  2. The effect of N. Sativa on:

I. Oxidative stress by measuring MDA II. Inflammation by measuring IL1B as inflammatory markers

B. Safety will be done through:

Monitoring of expected treatment related adverse effects (black seed oil and vonoprazan triple therapy ) will be done through the whole study period.

C. Symptoms evaluation using the Gastrointestinal symptom rating scale D. Assessment of patient's quality of life using SF36 questionnaire

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Helicobacter pylori infection is a highly prevalent chronic bacterial infection in humans worldwide affecting approximately 50% of the global population. H. pylori infection is highly prevalent in the Middle East and North Africa (MENA) region .

It may cause chronic gastritis, peptic ulcer disease, atrophic gastritis, and intestinal metaplasia that predispose to gastric cancer . Moreover, H. pylori may contribute to insulin resistance and metabolic syndrome as well as autoimmune and hematologic diseases . H. pylori was classified as a class I human carcinogen .

About 25 years ago, a proton pump inhibitor (PPI)-based regimen was introduced as a first-line treatment of H. pylori infection. PPI-based therapy showed a superior efficacy to non-PPI-based therapy in terms of H. pylori eradication.The PPI-based triple therapy, which consists of PPI, amoxicillin, and clarithromycin, has been a worldwide choice for H. pylori eradication. However, the treatment regimen is still a concern in light of the decreasing eradication rates owing to the increased antibiotic resistance of H. pylori.

Recently, vonoprazan, a novel potassium-competitive acid blocker, has been used in H. pylori eradication therapy in order to increase the eradication rate .

Vonoprazan (VPZ) works by competing for potassium on the luminal side of the parietal cell and causes rapid and reversible inhibition of H-K ATPase and therefore inhibits extended acid secretion. In contrast to PPIs, Vonoprazan is a more potent inhibitor of acid secretion. It has a rapid onset of action, less anti-secretory variability, greater safety, and better tolerability .

A meta-analysis of 10 studies by Jung et al. included research comparing the efficacy of a vonaprazan-based triple therapy group (vonoprazan 20 mg bid., amoxicillin 750 mg bid., and clarithromycin 200 or 400 mg bid. for 7 days) with that of a PPI-based triple therapy group (omeprazole 20 mg or lansoprazole 30 mg bid., amoxicillin 750 mg bid., and clarithromycin 200 or 400 mg bid. for 7 days). The eradication rates of vonoprazan-based triple therapy and PPI-based triple therapy were 87.9% and 72.8% (pooled risk ratio [RR] 1.02, 95% confidence interval [CI] 1.15-1.24), respectively.

The increasing rate of anti-H.Pylori drug resistance, medication costs, side effects, and the patient's incompliance make the treatment of H. pylori infection a global challenge. Therefore, there is a need to look for new safe, feasible, and affordable alternatives that are effective against H. pylori.

In recent years, the use of medicinal plants has been considered due to their potential effects on human health and the better management of diseases. Meanwhile, Nigella sativa is one of the most useful medicinal plants, which has been traditionally used for the treatment of many acute and chronic diseases and the promotion of human health.

The seeds of N. sativa, commonly known as black seed or black cumin, have rich biological active compounds such as thymoquinone (TQ), dithymoquinone, nigellicine, nigellidine, thymol, and carvacrol. All these compounds are synergistically responsible for beneficial pharmacological properties ; including antioxidant, anti-inflammatory, anticancer, antimicrobial, antiparasite, immunopotentiating action, gastroprotective, hepatoprotective, hypoglycemic, analgesic effects, and so forth.

In various studies, the antibacterial effects of this plant and its ingredients have been proven. The essential oil of N. sativa and its components like TQ and hydrothymoquinone were reported to be lethal to some Gram-negative and Gram-positive bacteria.

In an in vitro experiment, N. sativa extract inhibited the growth of all H. pylori strains within 60 min. The essential oil obtained from N. sativa was found to be safer than the volatile oil against different cell lines. Human case reports indicated allergic contact dermatitis following the use of some preparations containing N. sativa. However, clinical trials did not report any severe adverse effects following consumption N. sativa.

In a clinical trial, it was shown that N. sativa seed powder possessed anti-H. pylori activity comparable to triple therapy and improved dyspepsia symptoms in infected patients. It seems that the combination of N. sativa with antibiotics can reduce the resistance of H. pylori colonies and improve antibiotic efficacy.

H. pylori infection induces an inflammatory response that is also oxidative. The gastric epithelium and the bacteria induce production of interleukin-8 (IL-8) and malondialdehyde (MDA) that contributes to the generation of great amounts of toxic reactive oxygen species (ROS), with marked infiltration of inflammatory cells, and can elicit induction of interleukin-1β (IL-1β), interleukin-6 (IL-6), IL-8, interleukin-12 (IL-12), tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) .

IL-1β has biological effects that qualify it as arguably the most important cytokine in the gastrointestinal tract. Its proinflammatory properties contribute to the defence against pathogens, its antisecretory and cytoprotective effects contribute to the healing process following challenge to the integrity of the mucosa, and its acid inhibitory effects may have a profound effect on the natural history of H pylori infection.

Several studies have shown that NS has been proven to have antioxidant capabilities by reducing the production of reactive oxygen species (ROS), superoxide dismutase (SOD) and malondialdehyde (MDA).

Previous researches showed that supplementation of NS would significantly decrease the production of MDA and SOD in patients compared to controls.Interestingly, N. sativa Interestingly, TQ was found to exert its anti-inflammatory properties through the prevention of the expression of IL-6, IL-1β, and cyclooxygenase-2 in experimental rats.

No clinical trial has yet evaluated the effects of N. sativa oil concurrent with vonoprazan based regimens on the eradication of H. pylori infection. Therefore, The investigators performed this trial to evaluate the anti-H. Pylori properties of N. sativa concurrent with vonoprazan triple therapy on the eradication of bacteria, dyspepsia symptoms and quality of life in patients with this infection. Furthermore, the investigators measured the effects of N. sativa on oxidative stress and inflammatory markers in infected patients.

Study Type

Interventional

Enrollment (Estimated)

90

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
      • Zagazig, Egypt
        • Recruiting
        • GIT department zagazig university hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female patients
  • Age 18 to 75 years old
  • Patients with confirmed H. pylori infection by stool Ag test who had not received prior eradication therapy

Exclusion Criteria:

  • History of hypersensitivity / allergy to any of the study drugs i.e., Esomeprazole, vonoprazan, penicillin, or clarithromycin
  • History of previous H. pylori eradication therapy
  • History of using PPIs, antibiotics that affect H. pylori within 4 weeks
  • History of gastric malignancy or surgery
  • Serious cardiovascular, pulmonary, renal, hepatic disorders or active malignancy
  • Pregnancy or breast feeding
  • History of drug abuse or active alcohol abuse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group 1 , Black seed oil group
45 patients will receive they will receive 1800 mg (4 soft gelatin capsules of 450 mg) black seed oil (2 capsules twice daily 30 min after the meal) for 6 weeks plus vonoprazan-based triple therapy ( conventional therapy ) consists of vonoprazan 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily for 14 days
Drug: Black Seed Oil Cap/Tab
possessed anti-H. pylori activity comparable to triple therapy and improved dyspepsia symptoms in infected patients
Other Names:
  • Baraka 450 mg
Drug: Vonoprazan, Amoxicillin and Clarithromycin
H pylori vonoprazan based treatment
Active Comparator: Group 2 , control group
This group consists of 45 patients, who will receive vonoprazan-based triple therapy(conventional therapy ) consists of vonoprazan 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily for 14 days
Drug: Vonoprazan, Amoxicillin and Clarithromycin
H pylori vonoprazan based treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stool antigen test at baseline ( pre-intervention)
Time Frame: at baseline for diagnosis of helicobacter pylori (before start of triple therapy )
Stool Antigen Test: The test is qualitative and is based on the detection of H. pylori antigen in human feces ( positive test )
at baseline for diagnosis of helicobacter pylori (before start of triple therapy )
Change of Stool antigen test after 4 weeks from triple therapy
Time Frame: after 4 weeks from triple therapy
evaluate successful eradication of helicobacter pylori by negative stool Ag test
after 4 weeks from triple therapy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in MDA (oxidative stress marker) levels
Time Frame: change from baseline at 6 weeks
For evaluating the effect of N. Sativa on oxidative stress analysis for measuring levels of MDA and IL_1B using ELISA Kits.
change from baseline at 6 weeks
Change in Interleukin 1B ( inflammatory markers ) levels
Time Frame: change from baseline at 6 weeks
effect of Nsativa on inflamatory markers
change from baseline at 6 weeks
"Gastrointestinal symptom rating scale"
Time Frame: change from baseline at 6 weeks
• Symptoms will be assessed using "Gastrointestinal symptom rating scale"GSRS is a validated GI questionnaire that utilises a 7-level Likert scale (1-7), based on the intensity and frequency of GI symptoms experienced during the previous seven days. A higher score represents the main symptoms complained about by the patients.
change from baseline at 6 weeks
SF36 questionnaire
Time Frame: change from baseline at 6 weeks
Quality of life of patients will be assessed using the SF36 questionnaire
change from baseline at 6 weeks
Safety and tolerability
Time Frame: every week for 4 weeks

Personal interviews with open-ended questions via questionnaire and self-reporting will be conducted by telephone every other day after enrollment in order to access adverse events and side effect

The adverse effect that will be included in the questionnaire will be nausea, vomiting, bitter taste, skin rash, bloating, dizziness, headache, diarrhea, constipation, abdominal pain, and dry mouth or throat
every week for 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ain Shams University

Investigators

  • Principal Investigator: sara M zaky, ass.prof, faculty of pharmacy Ain Shams university
  • Study Chair: yasser A Elnaggar, prof, faculty of medicine Zagazig University
  • Study Chair: sara F Mohamed, lecturer, faculty of pharmacy Ainshams university

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2023

Primary Completion (Estimated)

June 1, 2024

Study Completion (Estimated)

August 1, 2024

Study Registration Dates

First Submitted

June 16, 2023

First Submitted That Met QC Criteria

July 14, 2023

First Posted (Actual)

July 24, 2023

Study Record Updates

Last Update Posted (Actual)

February 12, 2024

Last Update Submitted That Met QC Criteria

February 9, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Black seed oil with Vonoprazan

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Helicobacter Pylori Infection

Clinical Trials on Black Seed Oil Cap/Tab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe